CN110178028B - 用于肿瘤治疗的靶向阿霉素-金纳米缀合物 - Google Patents

用于肿瘤治疗的靶向阿霉素-金纳米缀合物 Download PDF

Info

Publication number
CN110178028B
CN110178028B CN201880006184.9A CN201880006184A CN110178028B CN 110178028 B CN110178028 B CN 110178028B CN 201880006184 A CN201880006184 A CN 201880006184A CN 110178028 B CN110178028 B CN 110178028B
Authority
CN
China
Prior art keywords
nanoconjugate
cancer
doxorubicin
dtdtpa
gold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880006184.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110178028A (zh
Inventor
R.坎南
A.扎姆布雷
A.厄彭德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Missouri–St. Louis
Original Assignee
University of Missouri–St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Missouri–St. Louis filed Critical University of Missouri–St. Louis
Publication of CN110178028A publication Critical patent/CN110178028A/zh
Application granted granted Critical
Publication of CN110178028B publication Critical patent/CN110178028B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201880006184.9A 2017-01-09 2018-01-09 用于肿瘤治疗的靶向阿霉素-金纳米缀合物 Expired - Fee Related CN110178028B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444114P 2017-01-09 2017-01-09
US62/444,114 2017-01-09
PCT/US2018/012882 WO2018129501A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Publications (2)

Publication Number Publication Date
CN110178028A CN110178028A (zh) 2019-08-27
CN110178028B true CN110178028B (zh) 2021-04-27

Family

ID=62791162

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880006184.9A Expired - Fee Related CN110178028B (zh) 2017-01-09 2018-01-09 用于肿瘤治疗的靶向阿霉素-金纳米缀合物

Country Status (12)

Country Link
US (1) US20210015944A1 (enExample)
EP (1) EP3568694B1 (enExample)
JP (1) JP7017258B2 (enExample)
KR (1) KR102568577B1 (enExample)
CN (1) CN110178028B (enExample)
AU (1) AU2018205349B2 (enExample)
BR (1) BR112019013469A2 (enExample)
CA (1) CA3048908A1 (enExample)
ES (1) ES2912286T3 (enExample)
MX (1) MX2019008233A (enExample)
WO (1) WO2018129501A1 (enExample)
ZA (1) ZA201904736B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치
CN113797353B (zh) * 2020-06-12 2023-10-20 南京工业大学 一种放化疗联合治疗试剂及其制备方法
CN112494660B (zh) * 2020-12-22 2023-11-21 上海交通大学 纳米靶向药物的制备方法及在治疗胃癌中的应用
US12485484B2 (en) 2022-05-17 2025-12-02 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Seedless synthesis of anisotropic gold nanoflowers with cellular control and drug delivery applications
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates
CN120713846B (zh) * 2025-07-14 2026-03-31 湖南省妇幼保健院 基于铜离子和多柔比星的纳米级配位聚合物NP@DoxCu及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014812A3 (en) * 2008-07-30 2010-03-18 The Research Foundation Of State University Of New York Peptide compositions and methods of use
CN105451721A (zh) * 2013-02-19 2016-03-30 财团法人卫生研究院 用于抗癌化疗法的笼状铂金纳米团簇

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US9605304B2 (en) * 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
PL3089997T3 (pl) * 2013-12-30 2020-09-07 The Curators Of The University Of Missouri Wieloskładnikowe nanomateriały au i metody syntezy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014812A3 (en) * 2008-07-30 2010-03-18 The Research Foundation Of State University Of New York Peptide compositions and methods of use
CN105451721A (zh) * 2013-02-19 2016-03-30 财团法人卫生研究院 用于抗癌化疗法的笼状铂金纳米团簇

Also Published As

Publication number Publication date
BR112019013469A2 (pt) 2020-01-07
RU2019125167A (ru) 2021-02-09
ES2912286T3 (es) 2022-05-25
ZA201904736B (en) 2021-04-28
JP7017258B2 (ja) 2022-02-08
CN110178028A (zh) 2019-08-27
KR102568577B1 (ko) 2023-08-18
US20210015944A1 (en) 2021-01-21
EP3568694B1 (en) 2022-02-16
WO2018129501A1 (en) 2018-07-12
EP3568694A4 (en) 2020-12-30
RU2019125167A3 (enExample) 2021-09-13
MX2019008233A (es) 2019-10-17
AU2018205349A1 (en) 2019-06-27
AU2018205349B2 (en) 2022-09-29
EP3568694A1 (en) 2019-11-20
JP2020504130A (ja) 2020-02-06
CA3048908A1 (en) 2018-07-12
KR20190104333A (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
KR102568577B1 (ko) 종양 요법을 위한 표적화된 독소루비신-금 나노접합체
Ghosh et al. Targeted delivery of curcumin in breast cancer cells via hyaluronic acid modified mesoporous silica nanoparticle to enhance anticancer efficiency
Nigam et al. Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer
Muhammad et al. Acid degradable ZnO quantum dots as a platform for targeted delivery of an anticancer drug
Li et al. LHRH-peptide conjugated dextran nanoparticles for targeted delivery of cisplatin to breast cancer
Bai et al. A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: An in vitro study of targeted delivery of cisplatin to ovarian cancer cells
WO2018171164A1 (zh) 一种喜树碱类前药及其制备和应用
WO2011057216A1 (en) Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
JP2018526432A (ja) ナノ粒子をベースとした肝臓標的化療法および撮像
EP3089997B1 (en) Au multicomponent nanomaterials and synthesis methods
JP5873719B2 (ja) 白金含有化合物被覆ナノ粒子を含有するコンジュゲート
CN110167530A (zh) 基于纳米粒子的肝靶向治疗
CN106309375A (zh) 一种纳米粒制剂、其制备方法及应用
Lorenzoni et al. Organoselenium compounds as functionalizing agents for gold nanoparticles in cancer therapy
CN104491868A (zh) 新型基于抗体偶联化疗药物纳米adc及制备方法和应用
Zayed et al. Effect of Chemical Binding of Doxorubicin Hydrochloride to Gold Nanoparticles, Versus Electrostatic Adsorption, on the In Vitro Drug Release and Cytotoxicity to Breast Cancer Cells: Zayed et al.
HK40014034A (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
Ma et al. Redox-responsive self-assembled podophyllotoxin twin drug nanoparticles for enhanced intracellular drug delivery
RU2773707C2 (ru) Наноконъюгаты доксорубицин-золото направленного воздействия для терапии опухолей
Meng Self-assembled Nanostructures for Drug Delivery and its Surface Modification Method
Piantini et al. Synthesis of novel cancer selective theranostic nano vedices
Zayed et al. Synthesis of Bifunctional Polyethylene Glycol Derivatives for Simultaneous Gold Surface Coating and Binding of Hydroxyapatite
KR20210015717A (ko) 항암제 및 다공성 실리카 입자의 제조방법
Singhai et al. Colloid and Interface Science Communications
Kitajima et al. Design and Synthesis of 4-Chlorocolchicine-Derived Prodrug Capable of Forming Nanoparticles by Self-Assembly

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014034

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210427

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40014034

Country of ref document: HK